TORONTO, April 3, 2023 /PRNewswire/ - Greenbrook TMS Inc. (NASDAQ: GBNH) ("Greenbrook" or the "Company") today announced that the Company has amended its amended and restated master sales agreement ...

When treatments such as medication and therapy aren’t able to relieve the symptoms of depression or another mental health condition, there are other options available. A psychiatrist might suggest ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted clearance to a transcranial magnetic stimulation device as an adjunctive treatment for major ...

Detailed price information for Nrx Pharmaceuticals Inc (NRXP-Q) from The Globe and Mail including charting and trades.

While devices that stimulate the brain invasively have generally been available since 2002, and devices that do so non-invasively have been available since 2013, in recent years, the U.S. Food and ...

NeuroStar Advanced Therapy is a transcranial magnetic stimulation system that uses magnetic fields to induce neural activity in the cerebral cortex. The Food and Drug Administration (FDA) has cleared ...

BrainsWay has achieved a successful turnaround with positive adjusted EBITDA and cash flow in Q3/23. The company offers advanced TMS therapy devices and has numerous patents. There are plenty of ...

As previously announced, low dose D-cycloserine has been associated with augmentation of the antidepressant and antisuicidal response achieved by Transcranial Magnetic Stimulation (TMS). NRx has ...

The US Food and Drug Administration (FDA) granted 510K clearance to market a new transcranial magnetic stimulation (TMS) device, the MagVita TMS Therapy system from MagVenture, for treatment of adults ...

The only approved treatments for Alzheimer’s disease are medications with limited effectiveness and a risk of severe, sometimes deadly, side effects. That’s why scientists search for therapies that ...